US · Healthcare · Biotechnology
EPS came in at -0.48 against a street estimate of -0.59 — a beat of 18.6%.
Analysts rate Syndax Pharmaceuticals Inc a strong buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $39.45.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.32% |
| Kynam Capital Management, LP | 9.09% |
| The Goldman Sachs Group Inc | 5.64% |
| State Street Corp | 5.00% |
| Bank of America Corp | 4.80% |
| Vanguard Capital Management, LLC | 4.31% |
| Deerfield Management Co | 4.27% |
| Eversept Partners, LP | 3.26% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-14 |
| Material agreement · Q2 2026 | 2026-06-10 |
| Board / officer change · Q2 2026 | 2026-06-10 |
| Material agreement · Q2 2026 | 2026-06-04 |
| Proxy statement · Q2 2026 | 2026-04-30 |
| Quarterly report · Q1 2026 | 2026-04-30 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Syndax Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.